

REMARKS

Reconsideration of the above-identified patent application in view of the amendment above and the remarks below is respectfully requested.

No claims have been canceled, amended or added in this paper. Therefore, claims 1-26 are pending and under active consideration.

In the outstanding Office Action, the Patent Office states the following:

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Specifically, the Sequence Listing is incomplete, as SEQ ID NOS have not been provided for all sequences recited in the application (see, e.g., Figures 2-3). Appropriate corrections for compliance are required.

Furthermore, the specification fails to comply with one or more of the requirements of 37 CFR §1.821 through 1.825 because the specification recites sequences that lack description by the appropriate sequence identifier set forth in the "Sequence Listing" as required by 37 CFR §1.821(d). See, for example, Figures 2-3, and the descriptions thereof: neither the Figures nor their descriptions provide SEQ ID Nos for the sequences recited therein. Appropriate corrections for compliance are required. With respect to figures/descriptions lacking the necessary SEQ ID Nos, it is noted Applicant may either file substitute Figures that recite appropriate sequence identifiers or amend the brief description of the figures so as to set forth said sequence identifiers. See MPEP 2422.02..

In response to the foregoing, Applicant is submitting herewith a replacement Sequence Listing on paper, as well as a copy of the replacement Sequence Listing in computer readable form. The content of the replacement Sequence Listing on paper and in computer readable form is the same

and contains no new matter. This Sequence Listing is supported by the application as filed, for example, in Figs. 2 and 3.

In addition, Applicant has, in this paper, amended the specification to include the required SEQ ID NOs.

Accordingly, for at least the above reasons, the present requirement has been satisfied.

In conclusion, it is respectfully submitted that the present application is now in condition for allowance. Prompt and favorable action is earnestly solicited.

If there are any fees due in connection with the filing of this paper that are not accounted for, the Examiner is authorized to charge the fees to our Deposit Account No. 11-1755. If a fee is

required for an extension of time under 37 C.F.R. 1.136 that is not accounted for already, such an extension of time is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,


Kriegsman & Kriegsman

By: 

Edward M. Kriegsman
Reg. No. 33,529
665 Franklin Street
Framingham, MA 01702
(508) 879-3500

Dated: November 22, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 22, 2004



Edward M. Kriegsman
Reg. No. 33,529

Dated: November 22, 2004